Hussman Strategic Advisors’s 10x Genomics TXG Stock Holding History

Hussman Strategic Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Sell	42,000 -21,000	-33%	-$550K	0.37%	130
2026 Q1	$1.34M	Buy	+63,000	New	+$1.26M	0.29%	158
2023 Q4	–	Sell	-21,000	Closed	-$866K	–	297
2023 Q3	$866K	Buy	+21,000	New	+$1.09M	0.17%	215
2022 Q2	–	Sell	-3,100	Closed	-$236K	–	361
2022 Q1	$236K	Hold	3,100	–	–	0.05%	287
2021 Q4	$462K	Hold	3,100	–	–	0.1%	254
2021 Q3	$451K	Hold	3,100	–	–	0.1%	247
2021 Q2	$607K	Buy	+3,100	New	+$561K	0.13%	243
2020 Q3	–	Sell	-20,600	Closed	-$1.84M	–	311
2020 Q2	$1.84M	Sell	20,600 -10,150	-33%	-$791K	0.47%	86
2020 Q1	$1.92M	Sell	30,750 -10,500	-25%	-$819K	0.52%	62
2019 Q4	$3.15M	Sell	41,250 -10,250	-20%	-$616K	1%	22
2019 Q3	$2.6M	Buy	+51,500	New	+$2.85M	0.74%	45

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hussman Strategic Advisors's TXG Position: Q2 2026 in Review

Hussman Strategic Advisors reduced its 10x Genomics (TXG) stake by 33% in Q2 2026, selling an estimated $550K and leaving 42,000 shares worth $1.61M. The position accounts for 0.37% of the portfolio, ranked #130.

Hussman Strategic Advisors first reported a position in TXG in Q3 2019 and has held it in 11 quarters since. The position peaked at $3.15M in Q4 2019. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Hussman Strategic Advisors held 42,000 shares of 10x Genomics worth $1.61M as of Q2 2026.
Hussman Strategic Advisors sold 21,000 10x Genomics shares in Q2 2026, an estimated $550K.
10x Genomics made up 0.37% of Hussman Strategic Advisors's portfolio in Q2 2026, its #130 holding.
Hussman Strategic Advisors first reported a position in 10x Genomics in Q3 2019 and has held it in 11 quarters since.
Hussman Strategic Advisors's 10x Genomics position peaked at $3.15M in Q4 2019.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.